Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Key Points Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Review the current valuation for Eli Lilly and Co (LLY:XMEX) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Eli Lilly stock is a no-brainer buy right now. For Eli Lilly to reach a $1 trillion market cap within the next couple of years, it would need to rise by more than 50% from where it is today.

How Does Eli Lilly’s Valuation Look vs. The S&P 500? Going by what you pay per dollar of sales or profit, LLY stock looks very expensive compared to the broader market.

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

Eli Lilly and Bristol Myers Squibb have long been top value plays. However, Lilly's stock comes across as the superior value play due to prevailing market conditions. Investor Alert: Our 10 best ...

Eli Lilly continued to grow like a weed in the second quarter. The company’s dividend payout ratio is somewhat low. Depending on your confidence in the future, the stock’s valuation may be ...

Eli Lilly is the most likely healthcare stock to reach a $1 trillion valuation, and I believe it could hit that plateau by 2027. Eli Lilly's stock has surged close to 400% in five years.